Immuno Cure Holding (HK) Limited
Immuno Cure Holding (HK) Limited is a clinical-stage biotechnology company, with its headquarters situated at the Hong Kong Science Park. We specialise in the development of innovative DNA medicines and antibody immunotherapies to combat infectious diseases, inflammatory diseases, and cancers.
Company
Immuno Cure is a clinical-stage biotechnology company, with its headquarters situated at the Hong Kong Science Park. We specialise in the development of innovative DNA medicines and antibody immunotherapies to combat infectious diseases, inflammatory diseases, and cancers.
Immuno Cure possesses three patented technology platforms: the "PD-1-Enhanced DNA Vaccine Platform", the "Anti-Δ42PD1 Antibody Platform", and the "Vaccine Delivery Platform". Currently, we have two DNA vaccine candidates in clinical trial stages. The first candidate is ICVAX, a therapeutic DNA vaccine targeting HIV/AIDS, undergoing Phase 1 clinical trials. The second candidate is ICCOV, a preventive DNA vaccine against COVID-19, undergoing Phase IIa clinical trials.
Immuno Cure possesses three patented technology platforms: the "PD-1-Enhanced DNA Vaccine Platform", the "Anti-Δ42PD1 Antibody Platform", and the "Vaccine Delivery Platform". Currently, we have two DNA vaccine candidates in clinical trial stages. The first candidate is ICVAX, a therapeutic DNA vaccine targeting HIV/AIDS, undergoing Phase 1 clinical trials. The second candidate is ICCOV, a preventive DNA vaccine against COVID-19, undergoing Phase IIa clinical trials.
The information provided on this page is for reference only. Please refer to the latest information published by the partner company.